What Topical DMSO Can—and Cannot—Be Expected to Do

DMSO gel is easy to misunderstand. Dimethyl sulfoxide passes readily through skin and can change the absorption of substances around it.

Skin penetration, however, is not proof of pain relief. Human evidence for topical DMSO is limited, mixed, and specific to the condition and formulation studied. A positive result with one concentration cannot validate every gel sold online. Likewise, a study of short-term symptom relief cannot establish cartilage repair, tendon healing, or reversal of disease.

There is also an important regulatory distinction. The secondary medical references reviewed for this article describe the FDA-approved human use as prescription DMSO delivered into the bladder for interstitial cystitis or painful bladder syndrome—not an over-the-counter DMSO gel for arthritis, tendinopathy, injuries, or general pain. Because the available evidence does not include a current FDA approval record or prescribing label, that regulatory description should be understood as an attribution to those medical references rather than a complete independent review of every current FDA listing.

For anyone considering a purchase, the useful questions are therefore narrower:

• What condition is being treated?
• What concentration and formulation were actually studied?
• Does the label distinguish finished concentration from ingredient purity?
• Is the product intended for humans or animals?
• What medicines, skin residues, contaminants, and health conditions could alter the risk?
• Would trying it delay diagnosis or a treatment with better supporting evidence?

What DMSO gel is and why skin penetration matters

DMSO stands for dimethyl sulfoxide. It is a colorless, water-miscible solvent historically associated with wood-pulp and paper processing. It can dissolve a wide range of small molecules and has been investigated in dermatology primarily as a penetration enhancer—a substance that changes the skin barrier so other compounds can pass through it more readily. Proposed mechanisms include disruption of the organization of the outer skin barrier, altered partitioning, and increased solubility of a co-applied drug, according to a peer-reviewed dermatology review.

Topical DMSO is sold as a liquid, cream, gel, or component of a combination preparation. “Gel” does not identify a different active chemical. It describes a formulation in which DMSO is combined with water and potentially other ingredients to produce a thicker product.

That distinction matters when interpreting a study or label. A finding about a solution does not automatically apply to a gel. Nor does a finding about a gel containing a particular DMSO concentration apply to a cream or a more concentrated product.

Rapid absorption establishes exposure, not effectiveness. A substance can cross the skin without relieving pain, producing a clinically meaningful anti-inflammatory effect, or treating the cause of a condition. DMSO’s penetration-enhancing behavior provides a reason to study it as a drug-delivery vehicle, but controlled human evidence must still show that a particular formulation improves a defined outcome in a defined condition.

The same property creates an exposure-control problem. DMSO placed over lotion, topical medicine, cosmetics, cleaning residue, dirt, or another chemical may change how substances on that area are absorbed or how they affect the body. Product contaminants are also more concerning when the principal ingredient can facilitate skin penetration.

A gel may feel easier to spread or less likely to run than a liquid. Those practical impressions should not be converted into medical conclusions. The supplied evidence does not establish that DMSO gel is safer, less readily absorbed, more controllable, or more effective than liquid DMSO. Concentration, excipients, quantity, application area, skin condition, product quality, and co-exposures may matter more than whether a container says “gel” or “liquid.”

DMSO should also not be confused with MSM, or methylsulfonylmethane. They are related sulfur compounds, but they are not interchangeable products. Readers comparing the two can review this separate guide to what MSM supplement trials actually show.

FDA approval: bladder treatment is not approval of topical pain gel

Regulatory clarification: The secondary medical sources reviewed here describe prescription DMSO placed inside the bladder as the FDA-approved human use. They do not identify an FDA-approved over-the-counter DMSO gel for general topical pain relief. Healthline, for example, describes DMSO as FDA-approved only for interstitial cystitis and states that it is not FDA-approved for pain relief in its medically reviewed overview.

These categories should not be blended:

Category	Route and context	What the reported regulatory status does—and does not—mean
Prescription intravesical human use	DMSO liquid placed into the bladder by catheter for interstitial cystitis or painful bladder syndrome	The cited medical references describe this as the FDA-approved human use. That status applies to the specified product, route, indication, and conditions of use—not topical pain gel.
Topical human use	Gel, cream, or solution promoted or investigated for pain, arthritis, tendinopathy, wounds, scars, injuries, or inflammation	Availability and research interest do not establish FDA-reviewed safety or effectiveness for an over-the-counter pain indication, according to a medical overview of DMSO uses and risks.
Veterinary use	Topical products used for specified animal conditions, with some uses occurring outside the approved label under veterinary direction	VCA describes topical DMSO as approved in horses and dogs for acute swelling due to trauma and says other animal uses may be off-label. That is veterinary information, not human-use authorization or dosing guidance (VCA medication guide).

Approval is not attached to an ingredient in the abstract. Approval of one DMSO product or route does not validate:

• a gel applied through intact skin;
• a different concentration or formulation;
• an online seller’s product;
• use for arthritis, tendon pain, muscle soreness, wounds, or injuries;
• an animal-labeled product used by a person; or
• claims that DMSO repairs tissue or treats inflammation throughout the body.

Likewise, being able to buy a product without a prescription does not show that regulators reviewed it as an effective pain treatment. Retail availability describes access, not evidence.

Claims involving arthritis, cancer, scars, burns, wounds, headaches, injuries, and generalized pain should be treated as promoted or investigated uses unless evidence supports the exact indication. The mere presence of DMSO in a study is not enough. The study must also isolate its contribution, use an appropriate comparison, measure meaningful outcomes, and apply to the condition and product in question.

What the pain evidence shows, condition by condition

“Does DMSO work for pain?” is too broad a question. Osteoarthritis, inflammatory arthritis, tendon disorders, neuropathic pain, acute sprains, and complex regional pain syndrome have different causes and clinical courses. Evidence from one should not be casually transferred to another.

The topical literature also uses different concentrations, formulations, comparators, treatment periods, and outcomes. Much of it is old, small, heterogeneous, or available through secondary summaries rather than detailed primary reports. Where study year, sample size, or full design details are absent below, the supplied secondary source did not provide enough information to report them reliably.

Condition	Studied formulation or concentration	Reported result	Major limitations	Confidence
Tendinopathy or tendinitis	An older double-blind trial used 10% gel twice daily; another comparison involved 70% solution and a 5% DMSO comparison	Some studies reported less pain and inflammation, but findings were inconsistent; 70% solution did not outperform the 5% comparison	Older secondary summary; varying formulations; a low-concentration DMSO comparison may not be inert; no basis for a general regimen (PeaceHealth evidence summary)	Limited and mixed
Osteoarthritis	An older trial used 25% gel; other trials evaluated different preparations	One trial reported short-term pain relief, while other controlled research found no meaningful advantage over placebo	Small or older studies; inconsistent findings; odor can complicate blinding; no evidence of structural repair (McGill analysis)	Limited and conflicting
Complex regional pain syndrome	A secondary summary discusses 50% DMSO cream	Rated “possibly effective” for associated pain	Secondary assessment; does not establish an optimal product, schedule, duration, or application to other pain conditions (RxList summary)	Possible benefit, uncertain
Rheumatoid arthritis	Topical DMSO has been discussed or investigated	Effectiveness has not been established consistently	Autoimmune inflammatory disease cannot be inferred from osteoarthritis or tendon studies	Insufficient
Neuropathy and general nerve pain	Promoted use, without adequate condition-specific evidence in the supplied material	Effect not established	Neuropathy has multiple causes, and the evidence is not specific enough	Insufficient
Muscle soreness, sprains, and strains	Commonly promoted uses	No reliable general benefit established	Lack of adequate controlled, condition-specific evidence	Insufficient or absent
Wounds and other inflammatory conditions	Investigated in varied settings, sometimes with another drug or procedure	Some reports are favorable; others are uncertain	Heterogeneous conditions and combination treatments prevent broad conclusions	Investigational

Tendinopathy

An older double-blind trial summarized by PeaceHealth used 10% DMSO gel twice daily for elbow and shoulder tendinitis and reported reductions in pain and inflammation. The same source describes other favorable findings but also a double-blind trial in which 70% DMSO solution did not outperform a 5% DMSO comparison.

Several cautions follow:

1. A 5% DMSO comparison may not be biologically inert, so describing it as a conventional placebo may oversimplify the design.
2. Evidence involving 10% gel cannot establish that a 70% or 99% product works better.
3. A trial schedule is a research protocol, not a validated instruction for unsupervised treatment.
4. Symptom improvement does not establish tendon repair.

Osteoarthritis

One older trial reported short-term benefit from 25% DMSO gel, but the broader evidence is inconsistent. A critical review from McGill’s Office for Science and Society describes four osteoarthritis trials in a systematic review: higher-concentration trials were negative, while positive lower-concentration trials had methodological limitations. It also discusses a 12-week knee osteoarthritis trial that found no difference between DMSO alone and placebo in self-reported pain, physical function, or overall health.

DMSO’s recognizable odor can also make blinding difficult. If participants or investigators can infer who received the active formulation, expectations may influence subjective outcomes such as pain. That does not automatically invalidate every result, but it lowers confidence when trial methods do not address the problem convincingly.

Most importantly, pain relief is not disease modification. Even if a formulation reduces pain briefly, that does not show that it:

• restores cartilage;
• reverses osteoarthritis;
• repairs a damaged joint;
• corrects alignment or instability;
• prevents structural deterioration; or
• replaces established evaluation and treatment.

Complex regional pain syndrome

A secondary medical reference characterizes topical 50% DMSO cream as “possibly effective” for pain associated with complex regional pain syndrome. That is a much narrower conclusion than “DMSO treats pain.” It does not establish a universal product, quantity, frequency, treatment duration, or benefit-risk balance for self-care.

Other pain and inflammatory conditions

For rheumatoid arthritis, neuropathy, muscle soreness, sprains, strains, wounds, and general inflammation, the supplied evidence is preliminary, inconsistent, absent, or insufficiently condition-specific. Rheumatoid arthritis is not simply a more severe form of osteoarthritis. Neuropathy is not one disease. A recent muscle strain is not equivalent to chronic tendinopathy.

Combination studies also require special care. When DMSO is used with another medicine, procedure, or both, improvement cannot automatically be attributed to DMSO. It may be functioning primarily as a delivery vehicle, the companion treatment may be responsible, or the combination may work differently from either component alone. Without a suitable DMSO-free comparison, DMSO’s independent effect cannot be isolated.

The responsible conclusion is not that topical DMSO can never affect pain. It is that the evidence does not establish DMSO gel as a proven general pain treatment. Findings are condition-specific and constrained by inconsistent results, varying formulations, difficult blinding, incomplete study details, and limited long-term safety evidence.

Concentration, purity, and grade are different claims

DMSO labels often place several percentages and quality terms close together. Those statements may describe different attributes:

• Finished-product concentration is the proportion of the final gel represented as DMSO.
• Raw-ingredient purity is the claimed assay or purity of the DMSO before formulation.
• Contaminant testing asks what else is present and in what amounts.
• Grade terminology is a quality claim whose meaning depends on the standard and documentation behind it.

A finished gel can contain 70% DMSO while being made from DMSO that the seller calls 99.99% pure. There is no mathematical contradiction: one percentage describes the finished mixture, while the other describes the claimed source ingredient.

For example, one marketplace seller describes a finished product as 70% DMSO and 30% distilled water, while separately claiming that the DMSO ingredient is 99.99% pure and “pharmaceutical grade.” The listing provides no independent laboratory report substantiating those claims, so it illustrates label terminology rather than verified quality (marketplace listing).

A statement such as “99.99% pure” does not by itself answer:

• Was the finished gel tested or only the raw material?
• Which batch was tested?
• Who performed the test?
• When was testing completed?
• Which analytical method was used?
• Were relevant contaminants measured?
• Does the certificate match the lot being sold?
• Were the other ingredients and finished concentration confirmed?
• Is the product labeled for human topical use?

The research concentrations also need context. The cited secondary summaries discuss 10% gel in tendinopathy, 25% gel in osteoarthritis, and 50% cream in complex regional pain syndrome. Those numeric protocols are cited in the evidence table above and should not be treated as general dosing instructions.

Commercial concentrations vary even more widely. One veterinary retailer lists a 99% DMSO gel and explicitly warns that the product is not approved for human use (veterinary retailer listing). That illustrates both the concentration range and the danger of treating animal products as human equivalents.

Formulations containing 10%, 25%, 50%, 70%, or 99% DMSO are not interchangeable. A higher percentage means more DMSO relative to the rest of the listed formulation. It does not establish greater clinical benefit, better purity, safer use, better value, or closer alignment with the evidence.

Research schedules should not be converted into self-treatment directions. The supplied evidence does not establish one optimal human concentration, amount, application area, frequency, or duration across conditions.

Terms such as “pharmaceutical grade,” “medical grade,” “laboratory grade,” and “high purity” should be treated as claims requiring documentation. A useful certificate of analysis should:

1. identify the exact product and batch or lot;
2. name the testing laboratory;
3. provide a recent test date;
4. report the DMSO assay and test method;
5. include relevant contaminant results;
6. clarify whether testing covered the raw material or finished gel; and
7. allow the document to be matched to the container being purchased.

An assay is narrower than a complete quality assessment. A certificate stating that a sample contained a particular percentage of DMSO does not necessarily verify every excipient, contaminant level, packaging characteristic, microbial concern, or label claim.

Side effects and the limits of the safety evidence

Reported effects associated with topical or other DMSO exposure vary with concentration, route, amount, formulation, duration, and the people exposed.

Reported local effects include:

• dryness;
• redness;
• irritation;
• itching;
• tingling;
• burning; and
• in some reports, blistering.

Reported sensory or systemic effects include:

• garlic- or oyster-like breath, body odor, or taste;
• headache;
• nausea or other gastrointestinal upset;
• dizziness; and
• drowsiness.

These reports do not mean that everyone experiences the effects, nor does the presence of odor or irritation show that the intended condition is improving. RxList groups these skin, sensory, gastrointestinal, neurologic, breathing, visual, allergic, and blood-related concerns across topical, oral, or other DMSO use; it does not provide a topical-gel-specific incidence rate.

The characteristic odor has a chemical explanation. After DMSO is absorbed, some can be metabolized to dimethyl sulfide, which may be exhaled and produce the recognizable smell.

A 2019 systematic review included 109 human studies involving multiple routes of DMSO administration. Gastrointestinal and skin reactions were among the most commonly reported categories. The authors concluded that most reported reactions were mild and transient and that reactions increased with dose (systematic review of human adverse reactions).

That review should not be stretched beyond its design. It was not limited to topical gel, and the studies were heterogeneous. It does not provide one dependable adverse-event rate for every gel, concentration, treatment duration, application area, or commercial product. “Most were mild” also does not mean that serious reactions cannot occur.

Severe allergic symptoms require immediate medical help, according to WebMD. Breathing or visual problems and marked skin reactions should likewise not be treated as routine nuisance effects. If significant symptoms appear during use, stop further exposure and obtain prompt professional advice rather than relying on an improvised home treatment protocol.

Eye safety remains an area of uncertainty. Historical animal findings included changes in the lens, while reports over time have been inconsistent. These animal findings do not establish that ordinary topical human use causes cataracts. They do reinforce that repeated or long-term human exposure has not been proved harmless.

Robust long-term human evidence is lacking for repeated topical exposure and possible effects involving the skin, eyes, liver, kidneys, blood, or wider systemic exposure. These are unresolved questions, not established predictions that every user will experience organ injury.

DMSO should therefore not be characterized as categorically safe or categorically unsafe. Risk depends on the circumstances, including:

• concentration and amount;
• route and formulation;
• exposed area;
• skin condition;
• purity and contaminants;
• co-applied substances;
• medication use;
• health status; and
• duration and repetition of exposure.

Short-term tolerance does not prove long-term safety. Someone who experiences no immediate burning or rash still faces unanswered questions if exposure is repeated, products are changed, larger areas are treated, or DMSO is combined with other substances.

Interactions and people who should not self-treat

Interaction concern begins with DMSO’s effect on penetration. If it changes the absorption of something applied to the same area, it may also change that substance’s effects or adverse effects. The concern is not limited to prescription creams; it can include nonprescription pain rubs, corticosteroid products, cosmetics, medicated patches, and chemical residues.

The interaction evidence is incomplete and sometimes conflicting. Secondary medical sources raise concerns involving blood thinners, steroids, sedatives, insulin, and other topical or systemic medicines. An older evidence summary reported no well-known medicine interactions while acknowledging that unknown interactions might exist.

Sparse or conflicting data do not prove the absence of clinically important interactions. A combination may be harmless, but it may also be inadequately studied or not assessed at the concentration and exposure under consideration.

Anyone using prescription medicines, multiple drugs, or nonprescription topical products should ask a clinician or pharmacist to review the complete list before considering DMSO. That review should include occasional medicines, supplements, injections, medicated patches, and substances applied to the same body area.

Insulin deserves particular attention. RxList reports that topical DMSO may alter insulin activity and advises close glucose monitoring under professional guidance. The same reference advises avoidance or professional consultation during pregnancy or breastfeeding and for people with liver, kidney, or certain blood disorders (precautions and interactions summary).

WebMD also advises people with diabetes, asthma, or liver or kidney conditions to consult a doctor before use and advises pregnant or breastfeeding people not to use DMSO. Reliable pregnancy and breastfeeding safety information is insufficient, so these are not settings for casual experimentation.

Professional advice is especially prudent for people with:

• diabetes or insulin use;
• asthma;
• liver or kidney conditions;
• certain blood disorders;
• significant allergy history;
• multiple prescription medicines; or
• topical medicines used on the intended application area.

A generic interaction list is not a substitute for an individual review. It cannot account for medicine dose and timing, application area, skin integrity, DMSO concentration, repeated exposure, glucose control, organ function, allergy history, or substances the user does not recognize as medicines.

No one should stop, start, or alter a prescribed medicine solely to make room for DMSO gel. The prior question is whether DMSO is justified for the condition and whether its uncertain benefit warrants the additional interaction and exposure complexity.

Contamination control: the practical issue marketing often misses

DMSO’s penetration-enhancing behavior is often presented as a benefit: it “gets in quickly” or “carries ingredients deeper.” For a shopper, the more important interpretation is exposure control. If DMSO changes passage through the skin, everything in contact with the treated area deserves attention.

Potential co-exposures include:

• body lotion or moisturizer;
• sunscreen;
• cosmetics or fragrance;
• prescription or nonprescription topical medicine;
• massage oil;
• cleaning-product residue;
• soil, grease, or workplace chemicals; and
• contaminants in the gel itself.

WebMD advises washing the skin before topical use and not applying other products to the same area until it has been washed again. It also warns that benefits and interaction evidence remain limited (DMSO precautions overview).

This safety guidance does not validate DMSO as effective for pain, arthritis, or any other promoted use. It addresses unintended exposure.

Industrial-grade DMSO should not be used for therapeutic self-treatment. The supplied medical sources warn that industrial material may contain impurities that DMSO can help carry through the skin. Dilution does not establish that contaminants have been removed or that the resulting mixture is suitable for human topical use.

A high DMSO assay also does not prove that a product is appropriately formulated. “99% DMSO” and “free from relevant contaminants” are different statements. The first addresses proportion or assay; the second requires appropriate contaminant testing. Neither statement alone confirms label accuracy or suitability for human use.

The evidence does not establish a validated waiting period after DMSO application before another topical product can be used or the area can contact other materials. Inventing a universal interval would create false precision.

When to escalate: Stop further exposure and seek prompt professional medical help for severe allergic symptoms, breathing trouble, significant blistering, visual symptoms, or marked systemic illness. Severe allergic reactions are identified as requiring immediate help in WebMD’s medical overview; other serious symptoms should not be managed with an improvised home decontamination or overdose protocol.

How to evaluate a product without mistaking marketing for evidence

A DMSO product page can look detailed while omitting the information most relevant to safety. Concentration, a purity slogan, customer reviews, and a photograph of a jar do not amount to clinical evidence or independent quality verification.

Use a neutral checklist rather than ranking products by concentration or popularity.

Label and manufacturer checklist

• What is the finished DMSO concentration?
• Is there a complete ingredient list, including water, thickeners, preservatives, and other active ingredients?
• Is the product labeled for humans, horses, dogs, or another species?
• Does it carry a warning against human use?
• Is the manufacturer clearly identified?
• Is there reliable contact information?
• Is there a lot or batch number?
• Is there an expiration, manufacturing, or testing date?
• Does the label provide storage and container information?
• Is there current independent testing for the exact batch?
• Does that testing address contaminants as well as DMSO assay?
• Are contraindications, interactions, and adverse effects addressed?
• Does the seller separate marketing claims from demonstrated indications?

Certificate-of-analysis checklist

A useful certificate of analysis should match the product’s batch, identify the testing laboratory, provide a current date, explain what sample was tested, and report the method and result for DMSO assay. It should also include relevant contaminant results rather than only restating “99.9%” or “99.99% pure.”

A generic certificate, an undated image, or a report for a different lot offers limited assurance. So does a document produced entirely by the seller without clear laboratory identification. Independent testing is most informative when the relationship among the sample, batch, laboratory, method, and retail container can be checked.

Seller claims, marketplace ratings, testimonials, prices, and terms such as “pharmaceutical grade” do not establish clinical effectiveness. They also do not independently verify composition. A favorable review may describe texture, delivery, odor, or personal experience, but it cannot reveal contaminant levels or determine whether improvement was caused by DMSO.

The marketplace example of a 70% gel is useful only for understanding terminology. Its seller describes a 70/30 formulation and separately claims 99.99% purity for the DMSO ingredient, but the listing supplies no clinical evidence, contraindication review, or independent substantiation of that purity statement. It should not be treated as a product endorsement.

Human versus veterinary DMSO

Veterinary DMSO is used under veterinarian direction for specified animal conditions. Animal labels can contain species-specific indications, application limits, precautions, interactions, and warnings.

Veterinary concentrations, approvals, products, and schedules must not be extrapolated to humans. An animal application limit is not a basis for calculating a human dose, and a warning that a veterinary product is not approved for human use should be taken at face value.

A practical decision framework has five steps:

1. Clarify the condition. “Pain” is not a diagnosis. Determine whether the problem is osteoarthritis, inflammatory arthritis, tendinopathy, neuropathy, an acute injury, or something requiring prompt evaluation.
2. Check the actual evidence level. Look for controlled human evidence involving the same condition, formulation, and concentration—not testimonials or studies of unrelated pain.
3. Review medicines and health risks. Ask a clinician or pharmacist to consider the complete medication list, pregnancy or breastfeeding, diabetes, allergies, and liver, kidney, respiratory, or blood conditions.
4. Reject unsuitable products. Do not use industrial material or a veterinary product for human self-treatment. Be skeptical of products without complete ingredients, traceable manufacturing information, intended-species labeling, and batch-specific testing.
5. Do not delay established care. An inadequately supported topical product should not postpone diagnosis or treatment with a clearer benefit-risk basis.

DMSO gel is unusual because it crosses the skin barrier readily and may change the absorption of other substances. That property calls for greater caution; it does not prove benefit. Current evidence does not justify presenting topical DMSO as a proven general pain treatment, an FDA-approved arthritis gel, or a way to repair damaged tissue.

Is DMSO gel FDA-approved for topical pain relief?

The secondary medical sources reviewed here do not identify an FDA-approved over-the-counter DMSO gel for general topical pain relief. They describe the approved human use as prescription DMSO placed into the bladder for interstitial cystitis or painful bladder syndrome.

Approval for one route and condition does not extend to a topical formulation or another indication. Retail availability also does not establish FDA-reviewed effectiveness for pain. Because no current primary FDA approval record was included in the reviewed evidence, this answer is deliberately limited to what the cited secondary medical sources report.

Is a 99% DMSO gel stronger or better than a 70% gel?

A 99% gel contains a greater stated proportion of DMSO than a 70% gel, but “higher concentration” is not the same as “clinically better.” Available research has used several concentrations with mixed results, including a comparison in which 70% solution did not outperform a 5% DMSO comparison.

Higher concentration has not been established as more effective, safer, purer, or better value. Concentration also says nothing by itself about contaminant testing, finished-product quality, or whether the product is intended for humans.

Why can DMSO cause garlic-like breath or body odor?

After DMSO is absorbed, some can be converted to dimethyl sulfide, a metabolite associated with garlic- or oyster-like breath and body odor. The odor reflects exposure and metabolism; it is not evidence that pain or inflammation is improving, as discussed in the human adverse-reaction review.

Is DMSO gel safer or less readily absorbed than liquid DMSO?

The supplied evidence does not establish that gel is safer, less readily absorbed, more controllable, or more effective than liquid DMSO. DMSO’s ability to penetrate skin remains relevant across topical formulations.

A gel may be thicker and easier to keep in one place, but that practical characteristic does not prove a safer exposure. Concentration, ingredients, quantity, application area, skin condition, purity, and co-applied substances all matter.

Can veterinary DMSO gel be used by humans?

Veterinary DMSO gel should not be repurposed for human self-treatment. Animal products can have different concentrations, intended uses, labeling, precautions, and species-specific directions. At least one veterinary 99% gel retailer explicitly warns that its product is not approved for human use.

Veterinary schedules cannot be converted into human dosing. A person considering topical DMSO should instead discuss the intended condition, medicines, health risks, and evidence-supported alternatives with a qualified healthcare professional.